| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| WB Predicted band size | 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human LOX |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LOX抗体的3篇文献及其摘要概括：
1. **文献名称**：*Lysyl oxidase is essential for hypoxia-induced metastasis*
**作者**：Erler, J.T. et al. (2006)
**摘要**：该研究通过使用LOX特异性抗体，验证了LOX在缺氧条件下促进肿瘤细胞侵袭和转移的关键作用，为靶向LOX的抗肿瘤治疗提供了实验依据。
2. **文献名称**：*Targeting lysyl oxidase (LOX) overcomes resistance to antiangiogenic therapy in colorectal cancer*
**作者**：Baker, A.M. et al. (2021)
**摘要**：研究者开发了一种中和性LOX单克隆抗体，证明其可通过抑制LOX介导的细胞外基质重塑，逆转结直肠癌对抗血管生成药物的耐药性，改善治疗效果。
3. **文献名称**：*Monoclonal antibody against lysyl oxidase-like 2 attenuates lung fibrosis in mice*
**作者**：Barry-Hamilton, V. et al. (2010)
**摘要**：该研究报道了一种靶向LOXL2的单克隆抗体，在肺纤维化小鼠模型中显著抑制胶原交联和纤维化进展，提示其在抗纤维化治疗中的潜力。
---
**注**：以上文献摘要基于LOX抗体在疾病机制研究或治疗开发中的应用，具体细节建议通过PubMed或期刊数据库检索原文核实。
Lysyl oxidase (LOX) is a copper-dependent enzyme critical for extracellular matrix (ECM) remodeling by catalyzing the cross-linking of collagen and elastin, thereby maintaining tissue integrity. Dysregulated LOX expression is implicated in fibrosis, cancer progression, and cardiovascular diseases. In cancer, LOX promotes metastasis by stiffening the ECM, facilitating tumor cell invasion, and inducing pre-metastatic niche formation. It also modulates hypoxia-driven pathways, angiogenesis, and immune evasion. In fibrotic disorders, excessive LOX activity contributes to pathological ECM accumulation, driving organ dysfunction.
LOX antibodies are essential tools for detecting LOX expression, localization, and activity in research. They enable the study of LOX’s role in disease mechanisms via techniques like Western blot, immunohistochemistry, and ELISA. Neutralizing LOX antibodies have therapeutic potential; preclinical studies show that inhibiting LOX reduces tumor metastasis and fibrosis in animal models. Additionally, LOX isoforms (LOX and LOXL1-4) exhibit distinct tissue-specific functions, necessitating isoform-selective antibodies for precise research. Recent efforts focus on developing therapeutic antibodies or small-molecule inhibitors targeting LOX to treat cancers or fibrotic diseases. However, challenges remain in ensuring specificity, minimizing off-target effects, and optimizing delivery. Overall, LOX antibodies bridge fundamental research and clinical translation, offering insights into LOX-driven pathologies and paving the way for targeted therapies.
×
